Albion News

The UCL Technology Fund (UCLTF), which provides funding and support for UCL’s most transformative innovations, has approved an investment of up to £1m in Professor Stephen Neidle’s ‘G-Quadruplex’ Targeting project, which has the potential to treat pancreatic and other cancers. Pancreatic cancer is devastating and almost always refractory to treatment, resulting in rapid and near-invariably fatal disease progression, usually within a few months of diagnosis. This outlook has not changed in over 40 years despite significant advances in the understanding of disease mechanisms, and the... read more
  Albion portfolio company, Proveca, announced that it has raised £4m to fund the commercial launch of Sialanar® and the development and commercialisation of its paediatric product portfolio. Sialanar® is a treatment for chronic pathological drooling in children, launched in the UK by Proveca, to be followed by the rest of Europe. The investment was led by Catapult Ventures, managers of the GM&C Life Sciences Fund, alongside Kreos Capital, a leading European provider of growth debt financing, in a deal advised by Longcross Advisers. The investment comes soon after the EU-wide PUMA (... read more
Albion has announced a £1.5m investment in automotive technology specialists SBD. Headquartered in Milton Keynes with offices in North America, Japan and India, SBD are specialists in automotive technology, providing independent research, evaluation and strategic services to 95% of the world’s leading car manufacturers. Having established a unique position in the sector, the company has recorded more than 50% revenue growth in the last financial year ended March 2016. Their clients include FCA Group, Ford, Jaguar Land Rover, Mitsubishi Motors, Nissan, Toyota and Volkswagen. The investment... read more
Albion has invested £3 million in Convertr Media to aid global expansion. Convertr is an award winning enterprise technology platform, launched in 2011 by entrepreneurs Emma Bowkett, CEO and Clive Brett, which helps advertisers enhance their digital marketing through real-time efficiencies in customer acquisition and data partnerships.   Bowkett, chief executive of Convertr Media said, “We are delighted to be working with Albion, at such an exciting time.  We are looking forward to the next phase of our company’s development, particularly with Robert’s expertise: he brings immense experience... read more
Albion announces that it has successfully completed the acquisition of OLIM Investment Managers (“OLIM”) from Close Brothers Group.  The acquisition was first announced on 27 September 2016, subject to regulatory approval. OLIM is a fund manager specialising in UK quoted equities, with around £500 million of assets under management. The completion of the acquisition further diversifies Albion’s investment management expertise into quoted equities and increases its assets under management and administration to over £950 million.  read more
Exco In Touch
Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, today announced that it has been recognized in Deloitte’s 2016 UK Fast 50 technology awards – securing the award in acknowledgment of the rapid growth achieved by the company over the course of the last four years. The accolade recognizes the success of Exco InTouch as the market leader in its field and pioneer of key innovations that have transformed the sector. More: read more
The Offers are now open for investment in the 2016/2017 and 2017/2018 tax years. All the documents associated with the Offers are available for viewing and download here read more
The UCL Technology Fund (UCLTF) has announced its participation in the formation of Achilles Therapeutics Ltd today (Wednesday), led by SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT). The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR). Achilles Therapeutics will design therapies to target truncal tumour neo-antigens – unique flags to the immune system present on the surface of every cancer cell*, which were first discovered by... read more
AGR Growth Report 2016
Small businesses are still upbeat about growth in the next two years, skills shortages are now the main barrier to growth and the East Midlands and East Anglia are the most optimistic regions. For the full report please visit the Publications page of the website which is within the 'About Us' box above. If you would like a hard copy of the report please email read more
Memstar has installed two ORBIS ALPHA systems in Bosch's German research and development facility in Renningen. The systems will be used in Bosch's development efforts for the next generation of MEMS devices. Introduced in 2014, ORBIS systems deliver the industry's most advanced single-wafer process capability for advanced MEMS manufacturing. memsstar is a leading provider of etch and deposition equipment and technology solutions to manufacturers of semiconductors and micro-electrical mechanical systems. "With the anticipated growth in the MEMS market, MEMS manufacturing must advance rapidly... read more